SGEN

Health Care Sector Update for 02/04/2016: MRK, SGEN

Top Health-care stocks:

JNJ: -0.7%

PFE: -0.3%

ABT: flat

MRK: -0.8%

AMGN: flat

Health-care shares were mainly lower in pre-market trade on Thursday.

In health-care stocks news, pharmaceutical company Merck & Company ( MRK ) said the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND (fosaprepitant dimeglumine) to prevent nausea and vomiting in patients receiving chemotherapy.

Shares in the company were 0.8% lower at $49.64 pre-bell. The company has traded between $45.69 and $61.70 over the past 52 weeks.

And Seattle Genetics ( SGEN ) said it will receive a one-time $20 million milestone payment under its ADCETRIS collaboration with Takeda Pharmaceutical Company.

Shares in the company unchanged at $32.31 pre-bell. The company has traded between $29.31 and $52.33 over the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.